Exploring Hyperfine, Inc. (HYPR) Investor Profile: Who’s Buying and Why?

You look at a company like Hyperfine, Inc. (HYPR), a medical technology firm still in its high-growth, pre-profit phase, and the first question is always: who is actually buying this story? Honestly, the investor profile is a classic mix of high-conviction venture capital and patient index funds, but the numbers tell the real tale of risk appetite right now.

In the third quarter of 2025, Hyperfine pulled in $3.4 million in revenue, a solid 27% sequential jump, but still posted a net loss of $11.0 million, which is the kind of burn rate that keeps a realist up at night. Still, institutional money is moving in; as of the most recent filings, major players like Vanguard Group Inc. hold over 3.5 million shares, and even a behemoth like BlackRock, Inc. holds 575,673 shares, demonstrating a belief in the long-term potential of their portable Swoop® brain imaging system. These institutions collectively own around 14.5% of the company, showing that while the stock trades around the dollar mark, smart money is defintely betting on the long-term adoption of a device with a record average selling price of $361,000. So, are they buying the growth story, or just the index? Let's break down who's accumulating shares and why they're willing to stomach that $11.0 million quarterly loss for a piece of the next-generation medical device market.

Who Invests in Hyperfine, Inc. (HYPR) and Why?

The investor profile for Hyperfine, Inc. (HYPR) is unusual for a publicly traded medical device company, characterized by a high concentration of retail and insider ownership, which signals a strong belief in the company's disruptive technology but also contributes to significant stock volatility. The core takeaway is that the majority of the float is held by individual investors who are betting on the long-term, high-growth potential of the portable MRI market.

Key Investor Types: Retail, Institutional, and Insiders

When you look at the ownership structure of Hyperfine, Inc., the first thing that jumps out is the dominance of the individual investor. Approximately 61.01% of the company is owned by retail investors, which is a massive portion for a Nasdaq-listed stock. This high retail ownership, plus a substantial insider stake, means the stock can move sharply on news.

The institutional ownership is relatively low, hovering around 11.25% to 14.46% as of late 2025, which reflects the company's early-stage, pre-profit profile and the speculative nature of the investment. Still, the roster includes heavyweight passive and active funds. For example, top institutional holders include Vanguard Group Inc, Fosun International Ltd, Northern Trust Corp, and BlackRock, Inc., which collectively hold millions of shares.

Insiders, including the founder, hold a significant stake, about 27.75% of the company, with Jonathan M. Rothberg being the largest individual shareholder, owning over 17.06 million shares. This high insider ownership is a double-edged sword: it shows strong alignment with long-term success but can also limit the available public float.

• Retail Investors: 61.01% ownership, driving volatility.
• Institutional Investors: ~11.25% ownership, including passive index funds.
• Insiders: 27.75% ownership, signaling founder commitment.

Investment Motivations: Why They're Buying

Investors are drawn to Hyperfine, Inc. primarily for its growth prospects and its unique market position with the Swoop® system, the first FDA-cleared, AI-powered portable MRI system. The investment thesis is simple: accessible, point-of-care brain imaging is a massive, underserved market globally. You're buying into a technology that could redefine medical diagnostics.

The financial data from the 2025 fiscal year shows why this is a high-risk, high-reward growth play. Management is guiding for full-year 2025 revenue of approximately $13 million to $14 million, with a significant Q4 guidance raise to $5 million to $6 million. That sequential growth is what excites investors, plus the Q3 2025 gross margin expanded to a record 54%, indicating improving unit economics. However, the net loss widened to $11.02 million in Q3 2025, and the full-year cash burn is expected to be in the range of $29 million to $31 million. This is defintely a story of sacrificing near-term profit for market capture.

The key drivers for institutional accumulation in 2025 are:

• Disruptive Technology: The Swoop® system's ability to deliver imaging at the bedside.
• Commercial Expansion: Entry into the neurology office market and international expansion, like the first installation in Norway.
• Product Innovation: The launch of the next-generation Swoop® system and Optive AI™ software.

Investment Strategies: The Long-Term Growth Bet

The strategies employed by Hyperfine, Inc. investors largely fall into two camps: long-term growth and short-term speculation. The presence of large index and mutual funds, such as those managed by Vanguard Group Inc and BlackRock, Inc., indicates a passive, long-term holding strategy, often through Schedule 13G filings (a passive investment of over 5%). They are holding the stock as part of a broader index, essentially betting on the entire medical technology sector's future.

For active investors, the strategy is pure growth investing, looking past the current negative earnings per share (EPS) of -$0.14 in Q3 2025. They are focused on the company's ability to execute its commercial plan and reduce its cash burn, which is projected to decline by 22% at the midpoint compared to 2024. Given the strong balance sheet with a minimal debt-to-equity ratio of 0.01, the company has the liquidity to fund its growth for now. You can learn more about the company's journey and mission here: Hyperfine, Inc. (HYPR): History, Ownership, Mission, How It Works & Makes Money.

Here's the quick math: the market is valuing the potential for a multi-billion dollar market, not the current $13-14 million in revenue. This is why the stock saw a 12.75% surge post-Q3 earnings on positive guidance, even though it had declined 47.73% month-to-date due to overall market sentiment and volatility.

The clear action for any investor is to monitor the sales trajectory of the next-generation Swoop® system and the cash burn rate. If the revenue growth accelerates beyond the 10-20% annual guidance, the growth thesis holds.

Institutional Ownership and Major Shareholders of Hyperfine, Inc. (HYPR)

For a company like Hyperfine, Inc. (HYPR), which is pioneering the portable Magnetic Resonance Imaging (MRI) market with its Swoop® system, institutional ownership tells a story about professional conviction in its long-term commercialization strategy. The current institutional ownership sits around 14.46% of the total shares outstanding as of November 2025, which is relatively low and suggests a significant portion of the stock is held by retail investors and insiders, including founder Jonathan M. Rothberg.

The total institutional shares held were approximately 10.12 million as of the end of the third quarter of 2025. This low percentage reflects the typical profile of a growth-stage medical device company with a smaller market capitalization-around $103.97 million as of November 20, 2025-where volatility is high and the investment is still considered speculative by many large funds.

Top Institutional Investors in Hyperfine, Inc.

When you look at the major holders, you see a mix of passive index giants and more active, growth-focused funds. The largest institutional investors are primarily those that track broad market indices, meaning their position is less about a specific bullish call on Hyperfine, Inc. and more about its inclusion in the Russell or other small-cap benchmarks. This provides a baseline of stability, even if the stock price is volatile.

Here's the quick math on the top holders as of the September 30, 2025, filing date:

Notice that Vanguard Group Inc. and BlackRock, Inc. are both in the top tier. These are the two largest asset managers globally, and their presence is typical for any publicly traded stock, but their combined holding is still relatively modest for a company of this size.

Recent Shifts in Institutional Ownership

The trend in institutional ownership for Hyperfine, Inc. has been mixed, which is what you defintely see in companies navigating a transition from R&D to full commercial growth. Looking at the third quarter of 2025, there were more institutions increasing their positions than decreasing them, which is a subtle positive signal.

The Q3 2025 filings show that 15 institutions increased their stakes, buying a net total of 550,510 shares. However, 9 institutions decreased their stakes, selling a net total of 324,565 shares.

• Vanguard Group Inc. increased its holding by 5.724%, adding 190,136 shares. This is a classic passive accumulation as the stock adjusts in the index.
• State Street Corp. saw a significant increase of 27.552%, adding 54,000 shares.
• Catalio Capital Management, LP, a venture-focused firm, decreased its position by -9.933%, selling 75,494 shares. This move suggests a more active re-evaluation of the near-term investment thesis.

Overall, the total number of institutional owners is around 51, which is a decent number, but the concentration in the top few passive funds means that active investment conviction is still building.

The Impact of Large Investors on HYPR's Strategy and Stock

The role of these large institutional investors in Hyperfine, Inc. is two-fold: they provide essential market functions and exert a quiet influence on corporate strategy, even with a smaller ownership percentage.

First, they provide liquidity and stability. The large, passive index funds like Vanguard and BlackRock are essentially permanent holders. They buy and hold, so their millions of shares act as a floor, reducing the day-to-day volatility that would otherwise be rampant in a low-float stock. Their presence is a stamp of inclusion in the major market indices, which opens the door to other institutional investors who are restricted to buying index-eligible stocks.

Second, the presence of active funds like Catalio Capital Management, LP-even with their recent trimming-signals that venture capital and growth equity are watching the commercialization of the Swoop® system. Their investment is a vote of confidence in the underlying technology and the company's mission to revolutionize patient care globally, as detailed in Hyperfine, Inc. (HYPR): History, Ownership, Mission, How It Works & Makes Money. When these active funds increase their stake, it often implies they see a clear path to significant revenue growth, which is critical since the company reported a net loss of $11 million in Q3 2025.

For you, the investor, the key takeaway is that institutional accumulation, which is tracked by the Fund Sentiment Score, suggests a higher level of professional buying interest. The fact that 15 institutions were net buyers in Q3 2025, despite the stock's volatility, suggests that the market is slowly starting to price in the company's strategic growth drivers, like the launch of the next-generation Swoop® system and the full commercial entry into the neurology office market.

Key Investors and Their Impact on Hyperfine, Inc. (HYPR)

You need to know who is betting on Hyperfine, Inc. (HYPR) because their conviction-or lack thereof-is a strong signal, especially in a high-growth, pre-profit medical technology company. The investor profile for Hyperfine, Inc. is a mix of foundational insider commitment and major, mostly passive, institutional money, with retail investors holding the largest chunk.

As of late 2025, institutional investors own between 11.25% and 14.46% of the company, but the real control lies with insiders, who hold about 27.75% of the shares. That's a critical distinction you must keep in mind.

The Anchor Investors: Insiders and Index Giants

The investor base is anchored by two distinct groups: the company's founder and the massive index fund managers. The largest individual shareholder is Jonathan M. Rothberg, the company's founder, who holds approximately 17.06 million shares, representing a significant 17.56% stake in the company. This holding was valued at about $19.62 million based on the stock price near November 2025.

The institutional side is led by the world's largest asset managers, which is typical for a publicly traded company, even a smaller one. The top institutional holders as of the third quarter of 2025 include:

• Vanguard Group Inc: The largest institutional holder, with 3,511,972 shares as of September 30, 2025.
• Fosun International Ltd: Holding 1,742,020 shares.
• Northern Trust Corp: Holding 1,115,414 shares.
• BlackRock, Inc.: Holding 575,673 shares as of September 30, 2025.

Here's the quick math: Vanguard Group Inc. and BlackRock, Inc. alone hold over 4 million shares, mostly through index funds, which means they are a stabilizing force, not a speculative one.

Investor Influence: Stability vs. Direction

The influence of these investors is two-fold. On one hand, the large, passive institutional holders like Vanguard and BlackRock provide a baseline of stability. They are generally 13G filers, meaning they are passive investors who buy because Hyperfine, Inc. is simply a component of a larger index fund, like the Vanguard Total Stock Market Index Fund. Their buying or selling is driven by index rebalancing, not an active view on the portable MRI market. Their presence is defintely a vote of confidence in the long-term viability of the public entity, but they don't dictate strategy.

On the other hand, the founder's massive 17.56% stake means he maintains significant influence over the company's strategic direction, particularly in key decisions like mergers, acquisitions, or major capital raises. When a founder holds that much, they set the tone.

The influence of activist investors is not a major factor here; the ownership structure points to a company driven by its founding vision and supported by passive institutional capital, with the majority 61.01% held by retail investors.

Recent Capital Moves and Investor Sentiment

Recent investor activity, particularly in the third quarter of 2025, shows mixed but notable moves. Some large institutions are adding to their positions, while others are trimming their holdings. This volatility mirrors the mixed investor sentiment following the Q3 2025 earnings report, where the stock surged 12.75% post-announcement but still declined 47.73% month-to-date.

Key institutional shifts as of Q3 2025 include:

• Buying: Vanguard Group Inc. increased its stake by 5.724%. State Street Corp. made a significant increase of 27.552%.
• Selling: Catalio Capital Management, LP reduced its holding by 9.933%.

This tells you that while the index funds are accumulating shares, active managers like Catalio are taking some chips off the table. The company itself also raised capital in October 2025, announcing a $17.5 million public offering, which is a key action that affects the balance of ownership by issuing new shares. You can learn more about the company's journey and financial structure at Hyperfine, Inc. (HYPR): History, Ownership, Mission, How It Works & Makes Money.

The table below summarizes the top institutional holdings and their recent changes, giving you a clear picture of who is moving money in and out of Hyperfine, Inc. as of Q3 2025.

What this estimate hides is the context of the recent insider selling: the Chief Operating Officer sold 1,405 shares in November 2025, but this was a non-discretionary sale to cover tax withholding obligations from vested restricted stock units, not a bearish signal.

Market Impact and Investor Sentiment

You're looking at Hyperfine, Inc. (HYPR) and wondering if the big money is still in the game, and honestly, the sentiment is a mixed bag-a volatile blend of institutional commitment and skittish near-term trading. The core takeaway is that while the stock has seen a sharp month-to-date decline of nearly 48%, major institutional investors like Vanguard Group Inc. and BlackRock, Inc. remain significant holders as of the end of Q3 2025, signaling a long-term belief in the portable MRI technology (Swoop system).

The market's reaction to the Q3 2025 earnings, reported on November 13/14, 2025, perfectly captured this tension. The stock price surged 12.75% immediately following the report, driven by management's raised Q4 revenue guidance to a midpoint of $5.5 million and the news of a $20.1 million capital raise in October, which extended the cash runway to mid-2027. But, to be fair, the stock still plummeted 47.73% month-to-date in November, reflecting investor anxiety over the persistent net loss, which widened to $11.02 million in Q3 2025.

• Insider Sentiment: Positive, with 9 different insiders recently buying shares.
• Technical Sentiment: Bearish, with the Fear & Greed Index showing 39 (Fear) as of November 2025.
• Key Financial Catalyst: Management expects full-year 2025 revenue to be between $13 million and $14 million.

Who Owns Hyperfine, Inc. (HYPR) and Why They're Buying

The investor profile for Hyperfine, Inc. is dominated by large, passive index funds and specialized healthcare/technology investors. This suggests that a significant portion of the ownership is non-discretionary (meaning they buy to track an index), which provides a stable floor, plus a few strategic players betting on the long-term disruption potential of the Swoop system.

Institutional ownership sits at about 14.46% of the outstanding shares. The largest holders are typically index fund behemoths, plus a few venture capital arms and specialized firms. They are buying because the commercial launch of the next-generation Swoop system and the new Opti AI software are seen as inflection points for adoption, particularly in the office and international markets. The recent $3.7 million grant from the Gates Foundation, announced in November 2025, also reinforces the global health mission and technology validation, which is a strong signal for mission-driven capital.

Here's a snapshot of the top institutional holders as of the Q3 2025 filing date (September 30, 2025):

Analyst Consensus and Key Investor Actions

The analyst community is split, but the most recent updates lean positive, which is a defintely good sign. The consensus rating is generally a 'Hold' or 'Buy,' but the average price target is anchored around $1.28. However, Lake Street Capital, a firm focused on emerging growth companies, reiterated a 'Buy' rating on November 19, 2025, with a price target of $2.00, representing significant upside from the current trading price. This indicates that some analysts believe the market is mispricing the company's near-term commercial execution.

The market is clearly focused on the cash burn (net cash burn excluding financing was $5.9 million in Q3 2025) and the pace of commercial adoption. The recent $20.1 million capital infusion in October 2025 was a critical de-risking event; it pushes the cash problem out to mid-2027, giving the company a longer runway to hit its revenue targets. This action is what institutional investors prioritize: reducing the risk of a near-term liquidity crunch. For a deeper dive into the company's financial stability, you should check out Breaking Down Hyperfine, Inc. (HYPR) Financial Health: Key Insights for Investors.

What this estimate hides, though, is the potential for faster adoption of the next-generation Swoop system, which boasts a record-high gross margin of 53.8% in Q3 2025. If Hyperfine, Inc. can maintain that gross margin while hitting the Q4 revenue guidance of $5 million to $6 million, the narrative shifts quickly from a cash-hungry startup to a scaling commercial entity. The market is waiting for proof of that scale.